Although these cases were likely random events, they illustrate the diagnostic and therapeutic challenges of GBM following HPV+ OPC and underscore the importance of personalized genomic assessment in HPV+ OPC survivors, who may develop non-head and neck SPMs unrelated to field cancerization.
Lovett et al. (Sun,) studied this question.